Scientific Fluency · Origins

Before the deal room, there was the bench.

From 1994 to 1997, before any commercial title, I worked at National Jewish Health under the mentorship of Dr. Lanny Rosenwasser, contributing to early-phase development of allergen immunotherapy for seasonal allergic disease — and, in parallel, characterizing the cellular mechanism underneath it.

The scientific fluency that shows up in a boardroom or a diligence call didn't come from a vocabulary list. It came from three years of actually running the assay.

1994–1997
National Jewish Health, mentored by Dr. Lanny Rosenwasser — three years at the bench before a single commercial role.
30 Years
From cellular-level characterization to today's molecular biomarker diagnostics for the same disease — see below.
The Work, Two Threads

One clinical, one mechanistic.

Two parallel research threads on the same disease process — allergic sensitization — approached from opposite ends: the clinic and the cell.

Clinical Development

Early-Phase Allergen Immunotherapy

  • Skin-prick screening of a panel of putative environmental allergens per patient
  • Identifying which markers reacted "hot" — the patient's actual sensitization profile
  • Compounding a purified vial from those reactive allergens for intramuscular dosing
  • Sub-threshold priming doses to desensitize the immune system without triggering a reaction
  • Maintenance re-dosing every 6–9 months to sustain tolerance once established

The goal: patients who no longer needed daily allergy medication to manage seasonal exposure.

Cellular Mechanism

T-Cell Antigen Presentation & Activation

  • Isolating the peripheral blood mononuclear cell (PBMC) fraction from allergic patients
  • Culturing and expanding a clonal population of T-cells specific to the putative allergens
  • Characterizing how those allergens were presented to and activated the T-cell response

The goal: understand the mechanism the clinical protocol was trying to modulate — not just observe that it worked.

The Field, Three Decades Later

1,517 proteins up-regulated. 27 down-regulated. All from a urine sample.

A 2023 study out of Beijing Shijitan Hospital used mass-spectrometry-based proteomics to compare urine samples from allergic rhinitis patients against healthy controls, identifying more than 1,500 differentially expressed proteins as candidate biomarkers for diagnosis and disease monitoring.

The disease process is the same one studied at the cellular level thirty years earlier. The diagnostic modality has moved from skin-prick panels and cultured T-cell clones to non-invasive molecular biomarkers — the same trajectory toward precision, data-driven diagnostics that runs through the rest of this site's thesis.

Na Liu, Jitu Wang, Xueyan Wang & Man Zhang — Heliyon, June 2023
The Throughline

Same disease, three eras of tooling.

1994–1997 Skin-prick panels + cultured T-cell clones National Jewish Health 2000s–2010s Component-resolved & molecular allergy diagnostics Field-wide shift 2023 Urine proteomics — 1,500+ candidate biomarkers Non-invasive, molecular The mechanism doesn't change. The tooling for finding and measuring it does — which is exactly the commercial opportunity in precision diagnostics.

Three eras of allergic disease research and diagnostics, from personal bench work through the published literature.

Why It Still Matters

What the bench actually taught, not just proved.

Mechanism Before Messaging

Understanding why a therapy works changes how you position it commercially — and how you spot when a claim is getting ahead of the biology.

Patient-Level Thinking

Every protocol was built around one patient's specific sensitization profile. That habit of mind carries directly into account-level and deal-level strategy.

Data Discipline at the Source

Running the assay yourself builds a different relationship with data quality than reading someone else's summary of it ever will.

Translational Fluency

Being able to sit with a bench scientist or a clinical KOL and actually follow the mechanism — not just nod along — is the difference between a vendor and a partner.

Scientific credibility isn't a slide. It's a track record.

Twenty-five years of commercial execution in life sciences, built on a foundation that started at the bench — not a marketing department.

Map Your Opportunity View Full Capabilities